LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 23

Search options

  1. Article ; Online: Oral human papillomavirus infection: hazard of intimacy.

    Schlecht, Hans P

    JAMA

    2012  Volume 307, Issue 7, Page(s) 724–725

    MeSH term(s) Animals ; Female ; Human papillomavirus 16/isolation & purification ; Humans ; Male ; Mouth/virology ; Mouth Diseases/epidemiology ; Papillomavirus Infections/epidemiology
    Language English
    Publishing date 2012-02-15
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2012.117
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Understanding Patients' Perspectives on Opt-Out, Incentivized, and Mandatory HIV Testing.

    Noland, Carey M / Vaughn, Nicole A / Sun, Sirena / Schlecht, Hans P

    International journal of health sciences

    2015  Volume 9, Issue 3, Page(s) 293–303

    Abstract: Background: Currently, widespread HIV testing is the best preventive action against further spread of the HIV epidemic. However, over 40% of the U.S. population has never been tested for HIV and 25% of those with HIV have never been tested. To increase ... ...

    Abstract Background: Currently, widespread HIV testing is the best preventive action against further spread of the HIV epidemic. However, over 40% of the U.S. population has never been tested for HIV and 25% of those with HIV have never been tested. To increase testing rates, in 2006 the CDC advised healthcare settings to conduct testing on an opt-out basis.
    Methods: Qualitative, semi-structured interviews with ten seropositive patients and ten seronegative were conducted to address the lack of studies investigating patients' acceptance of and attitude towards this and more novel testing models, e.g. incentivized or anonymous mandatory testing. Participants were asked about their HIV testing history and attitudes towards opt-out, incentivized, and mandatory anonymous HIV testing.
    Results: Major themes were identified using grounded theory data analysis. All participants were receptive to opt-out testing, and saw the removal of separate written consent as beneficial as long as patients were given the opportunity to consent in some form.
    Conclusion: Ultimately, both mandatory and opt-out testing were equally indicated by participants as being the most effective testing model at increasing testing rates. A firm understanding of patients' perspectives allows for development of effective HIV testing initiatives that are patient-sensitive and can substantially reduce HIV infection rates.
    Language English
    Publishing date 2015-11-25
    Publishing country Saudi Arabia
    Document type Journal Article
    ZDB-ID 2603595-9
    ISSN 1658-3639
    ISSN 1658-3639
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Images in HIV/AIDS. HIV-associated intestinal spirochetosis.

    Braza, Julia / Schlecht, Hans P

    The AIDS reader

    2007  Volume 17, Issue 11, Page(s) 551–552

    MeSH term(s) AIDS-Related Opportunistic Infections/etiology ; AIDS-Related Opportunistic Infections/pathology ; Adult ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/therapeutic use ; HIV Infections/complications ; HIV Infections/pathology ; Humans ; Immunohistochemistry/methods ; Intestinal Diseases/epidemiology ; Intestinal Diseases/microbiology ; Intestinal Diseases/pathology ; Male ; Spirochaetales Infections/diagnosis ; Spirochaetales Infections/drug therapy ; Spirochaetales Infections/pathology
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2007-11
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2039813-X
    ISSN 1053-0894
    ISSN 1053-0894
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Images in HIV/AIDS. HIV-associated lymphogranuloma venereum proctitis.

    Schlecht, Hans P / Panther, Lori A / Fugelso, Dana K

    The AIDS reader

    2007  Volume 17, Issue 3, Page(s) 145–6, 150

    MeSH term(s) AIDS-Related Opportunistic Infections/chemically induced ; AIDS-Related Opportunistic Infections/drug therapy ; Adult ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/therapeutic use ; Doxycycline/administration & dosage ; Doxycycline/therapeutic use ; Erythromycin/administration & dosage ; Erythromycin/therapeutic use ; Homosexuality, Male ; Humans ; Lymphogranuloma Venereum/diagnosis ; Lymphogranuloma Venereum/drug therapy ; Male ; Proctitis/diagnosis ; Proctitis/drug therapy
    Chemical Substances Anti-Bacterial Agents ; Erythromycin (63937KV33D) ; Doxycycline (N12000U13O)
    Language English
    Publishing date 2007-03
    Publishing country United States
    Document type Case Reports ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2039813-X
    ISSN 1053-0894
    ISSN 1053-0894
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: MACE RNA sequencing analysis of conjunctival squamous cell carcinoma and papilloma using formalin-fixed paraffin-embedded tumor tissue.

    Boneva, Stefaniya / Schlecht, Anja / Zhang, Peipei / Boehringer, Daniel / Lapp, Thabo / Mittelviefhaus, Hans / Reinhard, Thomas / Auw-Haedrich, Claudia / Schlunck, Guenther / Wolf, Julian / Lange, Clemens

    Scientific reports

    2020  Volume 10, Issue 1, Page(s) 21292

    Abstract: Recent advances in the field of biomedical research allow for elucidation of the transcriptional signature of rare tumors such as conjunctival squamous cell carcinoma (SCC). In this study we compare its expression profile to conjunctival papilloma (Pap) ... ...

    Abstract Recent advances in the field of biomedical research allow for elucidation of the transcriptional signature of rare tumors such as conjunctival squamous cell carcinoma (SCC). In this study we compare its expression profile to conjunctival papilloma (Pap) and healthy conjunctival tissue (Ctrl) and develop a classification tool to differentiate these entities. Seven conjunctival SCC, seven Pap and ten Ctrl were formalin-fixed and paraffin-embedded (FFPE) and analyzed using Massive Analysis of cDNA Ends (MACE) RNA sequencing. Differentially expressed genes (DEG) and gene ontology (GO) clusters were explored and the abundance of involved cell types was quantified by xCell. Finally, a classification model was developed to distinguish SCC from Pap and Ctrl. Among the most prominent DEG in SCC a plethora of keratins were upregulated when compared to Pap and Ctrl. xCell analysis revealed an enrichment of immune cells, including activated dendritic cells and T-helper type 1 cells (Th1), in SCC when compared to Ctrl. The generated classification model could reliably discriminate between the three entities according to the expression pattern of 30 factors. This study provides a transcriptome-wide gene expression profile of rare conjunctival SCC. The analysis identifies distinct keratins, as well as dendritic and Th1 cells as important mediators in SCC. Finally, the provided gene expression classifier may become an aid to the conventional histological classification of conjunctival tumors in uncertain cases.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Squamous Cell/diagnosis ; Carcinoma, Squamous Cell/metabolism ; Case-Control Studies ; Conjunctival Neoplasms/classification ; Conjunctival Neoplasms/diagnosis ; Conjunctival Neoplasms/metabolism ; Female ; Gene Expression Profiling ; Humans ; Male ; Middle Aged ; Papilloma/diagnosis ; Papilloma/metabolism ; Sequence Analysis, RNA ; Transcriptome ; Young Adult
    Language English
    Publishing date 2020-12-04
    Publishing country England
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-020-78339-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Weight-based loading of vancomycin in patients on hemodialysis.

    Brown, Merideth / Polisetty, Radhika / Gracely, Edward J / Cuhaci, Bulent / Schlecht, Hans P

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2011  Volume 53, Issue 2, Page(s) 164–166

    Abstract: We evaluated weight-based loading doses of vancomycin and resulting initial prehemodialysis concentrations. Modeling demonstrated modest correlation between dose administered, age, and initial concentration achieved. Actual body weight-based loading of ... ...

    Abstract We evaluated weight-based loading doses of vancomycin and resulting initial prehemodialysis concentrations. Modeling demonstrated modest correlation between dose administered, age, and initial concentration achieved. Actual body weight-based loading of vancomycin predictably achieves therapeutic initial concentrations in patients who receive hemodialysis.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/pharmacokinetics ; Body Weight ; Female ; Gram-Positive Bacterial Infections/drug therapy ; Humans ; Male ; Middle Aged ; Models, Statistical ; Plasma/chemistry ; Renal Dialysis/adverse effects ; Vancomycin/administration & dosage ; Vancomycin/pharmacokinetics
    Chemical Substances Anti-Bacterial Agents ; Vancomycin (6Q205EH1VU)
    Language English
    Publishing date 2011-07-15
    Publishing country United States
    Document type Evaluation Studies ; Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/cir322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: The growing problem of non-AIDS-defining malignancies in HIV.

    Pantanowitz, Liron / Schlecht, Hans P / Dezube, Bruce J

    Current opinion in oncology

    2006  Volume 18, Issue 5, Page(s) 469–478

    Abstract: Purpose of review: The incidence and spectrum of non-AIDS-defining cancers has continued to grow. As HIV-infected individuals live longer due to highly active antiretroviral therapy, their risk of dying from one of these cancers is increased. The recent ...

    Abstract Purpose of review: The incidence and spectrum of non-AIDS-defining cancers has continued to grow. As HIV-infected individuals live longer due to highly active antiretroviral therapy, their risk of dying from one of these cancers is increased. The recent literature pertaining to non-AIDS-defining cancers is reviewed.
    Recent findings: Recent epidemiological studies have identified higher rates of carcinoma of the anus, lung, breast, skin, conjunctiva, liver and prostate; hematopoietic malignancies such as Hodgkin's lymphoma, plasma-cell neoplasia and leukemia; and other neoplasms like melanoma and leiomyosarcoma in HIV-positive patients. The role of HIV-induced immunosuppression in the development of these non-AIDS-defining cancers appears less important than lifestyle habits like smoking and sun exposure, as well as coinfection with human papilloma, hepatitis B, hepatitis C and Epstein-Barr viruses.
    Summary: It is unclear whether the growing number of reports on non-AIDS-defining cancers reflects a true increased incidence or merely the product of increased surveillance, detection and reporting. Highly active antiretroviral therapy not only promotes longevity in the HIV-positive population, but may increase their risk of developing cancer like Hodgkin's lymphoma. Assertive prevention strategies are needed to adequately deal with non-AIDS-defining cancers in an aging and growing HIV-positive population.
    MeSH term(s) Anti-Retroviral Agents/therapeutic use ; Antiretroviral Therapy, Highly Active ; Causality ; Comorbidity ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Humans ; Incidence ; Neoplasms/epidemiology ; Neoplasms/virology ; Risk Factors
    Chemical Substances Anti-Retroviral Agents
    Language English
    Publishing date 2006-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/01.cco.0000239886.13537.ed
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists.

    Schlecht, Hans P / Schellhorn, Sarah / Dezube, Bruce J / Jacobson, Jeffrey M

    Therapeutics and clinical risk management

    2008  Volume 4, Issue 2, Page(s) 473–485

    Abstract: Treatment of HIV-1 infection has produced dramatic success for many patients. Nevertheless, viral resistance continues to limit the efficacy of currently available agents in many patients. The CCR5 antagonists are a new class of antiretroviral agents ... ...

    Abstract Treatment of HIV-1 infection has produced dramatic success for many patients. Nevertheless, viral resistance continues to limit the efficacy of currently available agents in many patients. The CCR5 antagonists are a new class of antiretroviral agents that target a necessary coreceptor for viral entry of many strains of HIV-1. Recently, the first agent within this class, maraviroc, was approved by a number of regulatory agencies, including the Food and Drug Administration. Herein we review the role of the CCR5 receptor in HIV-1 infection and potential methods to target it in anti-HIV-1 therapy. We review the various categories of agents and discuss specific agents that have progressed to clinical study. We discuss in detail the recently approved, first in class CCR5 antagonist, maraviroc, and discuss aspects of resistance to CCR5 antagonism and the potential role of CCR5 antagonism in the management of HIV-1 infection.
    Language English
    Publishing date 2008-08-18
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2186560-7
    ISSN 1178-203X ; 1176-6336
    ISSN (online) 1178-203X
    ISSN 1176-6336
    DOI 10.2147/tcrm.s1997
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients.

    Panther, Lori A / Schlecht, Hans P / Dezube, Bruce J

    The AIDS reader

    2005  Volume 15, Issue 2, Page(s) 79–82, 85–6, 88, 91

    Abstract: The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing. It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV ... ...

    Abstract The incidence of human papillomavirus (HPV)-related anal squamous cell carcinoma is increasing. It is likely that long-standing HIV-related immunosuppression plays a significant role in the pathogenesis of anal carcinoma; however, a direct HIV-HPV interaction has also been implicated. Using cervical cancer prevention as a paradigm, anal Pap smear screening as part of routine HIV preventive care has been proposed to detect and treat precancerous anal lesions in the hope of decreasing anal cancer rates. All HIV-positive patients with invasive cancer of the anal canal, particularly those with CD4+ cell counts greater than 200/microL and those receiving HAART, should be managed in the same manner as their HIV-negative counterparts.
    MeSH term(s) Anus Neoplasms/epidemiology ; Anus Neoplasms/pathology ; Biopsy, Needle ; Carcinoma, Squamous Cell/epidemiology ; Carcinoma, Squamous Cell/pathology ; Female ; HIV Infections/diagnosis ; HIV Infections/epidemiology ; Humans ; Immunohistochemistry ; Incidence ; Male ; Mass Screening ; Papillomaviridae/isolation & purification ; Papillomavirus Infections/diagnosis ; Papillomavirus Infections/epidemiology ; Precancerous Conditions/pathology ; Proctoscopy ; Prognosis ; Risk Assessment ; Survival Analysis ; United States/epidemiology
    Language English
    Publishing date 2005-02
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Review
    ZDB-ID 2039813-X
    ISSN 1053-0894
    ISSN 1053-0894
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study.

    Zentner, Isaac / Schlecht, Hans P / Khensouvann, Lorna / Tamuhla, Neo / Kutzler, Michele / Ivaturi, Vijay / Pasipanodya, Jotam G / Gumbo, Tawanda / Peloquin, Charles A / Bisson, Gregory P / Vinnard, Christopher

    BMC infectious diseases

    2016  Volume 16, Page(s) 242

    Abstract: Background: The cost and complexity of current approaches to therapeutic drug monitoring during tuberculosis (TB) therapy limits widespread use in areas of greatest need. We sought to determine whether urine colorimetry could have a novel application as ...

    Abstract Background: The cost and complexity of current approaches to therapeutic drug monitoring during tuberculosis (TB) therapy limits widespread use in areas of greatest need. We sought to determine whether urine colorimetry could have a novel application as a form of therapeutic drug monitoring during anti-TB therapy.
    Methods: Among healthy volunteers, we evaluated 3 dose sizes of rifampin (150 mg, 300 mg, and 600 mg), performed intensive pharmacokinetic sampling, and collected a timed urine void at 4 h post-dosing. The absorbance peak at 475 nm was measured after rifamycin extraction. The optimal cutoff was evaluated in a study of 39 HIV/TB patients undergoing TB treatment in Botswana.
    Results: In the derivation study, a urine colorimetric assay value of 4.0 × 10(-2) Abs, using a timed void 4 h after dosing, demonstrated a sensitivity of 92 % and specificity of 60 % to detect a peak rifampin concentration (Cmax) under 8 mg/L, with an area under the ROC curve of 0.92. In the validation study, this cutoff was specific (100 %) but insensitive (28 %). We observed similar test characteristics for a target Cmax target of 6.6 mg/L, and a target area under the drug concentration-versus-time curve (AUC0-8) target of 24.1 mg•hour/L.
    Conclusions: The urine colorimetric assay was specific but insensitive to detect low rifampin serum concentrations among HIV/TB patients. In future work we will attempt to optimize sampling times and assay performance, with the goal of delivering a method that can translate into a point-of-care assessment of rifampin exposure during anti-TB therapy.
    MeSH term(s) Adult ; Antitubercular Agents/analysis ; Antitubercular Agents/therapeutic use ; Antitubercular Agents/urine ; Botswana ; Colorimetry/methods ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Drug Monitoring/methods ; Female ; Healthy Volunteers ; Humans ; Male ; ROC Curve ; Rifampin/analysis ; Rifampin/therapeutic use ; Rifampin/urine ; Sensitivity and Specificity ; Specimen Handling ; Tuberculosis/drug therapy ; Tuberculosis/urine ; Urinalysis/methods
    Chemical Substances Antitubercular Agents ; Rifampin (VJT6J7R4TR)
    Language English
    Publishing date 2016-06-01
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Validation Studies
    ISSN 1471-2334
    ISSN (online) 1471-2334
    DOI 10.1186/s12879-016-1576-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top